CSX-1004 is under clinical development by Cessation Therapeutics and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CSX-1004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CSX-1004 is under development for the reversal of acute opioid over dose of fentanyl and carfentanil drugs. The drug candidate is a recombinant human immunoglobulin G (IgG) 1llambda monoclonal antibody specific for fentanyl and structurally related fentanyl analogs. It is administered through intravenous and subcutaneous route of administration.
Cessation Therapeutics overview
Cessation Therapeutics LLC is an pharmaceutical company which is engaged to develop novel vaccines for addiction-free world with the help of biotech innovation from addiction-based disorders. The company is headquartered in United States.
For a complete picture of CSX-1004’s drug-specific PTSR and LoA scores, buy the report here.